These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38112074)

  • 1. Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus.
    Paredes-Ruiz D; Martin-Iglesias D; Ruiz-Irastorza G
    Expert Rev Clin Immunol; 2024 Apr; 20(4):359-373. PubMed ID: 38112074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions.
    Ugarte A; Danza A; Ruiz-Irastorza G
    Curr Opin Rheumatol; 2018 Sep; 30(5):482-489. PubMed ID: 29870497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Clin Rheumatol; 2019 Oct; 38(10):2785-2791. PubMed ID: 31175481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Intern Med; 2019 May; 58(9):1257-1262. PubMed ID: 30626831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
    Takamasu E; Yokogawa N; Shimada K; Sugii S
    Lupus; 2019 Oct; 28(12):1473-1476. PubMed ID: 31575325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic lupus erythematosus: review of synthetic drugs.
    Tsang-A-Sjoe MW; Bultink IE
    Expert Opin Pharmacother; 2015; 16(18):2793-806. PubMed ID: 26479437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus.
    Yoshida M; Minowa K; Amano H; Asai Y; Yamaji K; Tamura N
    Lupus; 2021 Aug; 30(9):1378-1384. PubMed ID: 33966540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
    Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
    Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases.
    Ichikawa K; Kirino Y; Kunishita Y; Kishimoto D; Takase-Minegishi K; Yoshimi R; Nakajima H
    Mod Rheumatol Case Rep; 2021 Jul; 5(2):259-264. PubMed ID: 33533686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
    He F; Luo Q; Lei M; Fan L; Shao X; Hu K; Qin S; Yu N; Cao J; Yang L
    Clin Rheumatol; 2020 Sep; 39(9):2803-2810. PubMed ID: 32725351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.
    Mok CC; Ho LY; Tse SM; Chan KL
    Ann Rheum Dis; 2017 Aug; 76(8):1420-1425. PubMed ID: 28432050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts.
    Ruiz-Irastorza G; Ugarte A; Saint-Pastou Terrier C; Lazaro E; Iza A; Couzi L; Saenz R; Richez C; Porta S; Blanco P
    Autoimmun Rev; 2017 Aug; 16(8):826-832. PubMed ID: 28564619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Inoue Y; Ueno M; Tanaka Y
    Int J Rheum Dis; 2019 Mar; 22(3):434-442. PubMed ID: 30338639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus.
    Ruiz-Irastorza G; Ugarte A; Ruiz-Arruza I; Khamashta M
    Lupus; 2020 Sep; 29(10):1155-1167. PubMed ID: 32539657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Tsakonas E; Joseph L; Esdaile JM; Choquette D; Senécal JL; Cividino A; Danoff D; Osterland CK; Yeadon C; Smith CD
    Lupus; 1998; 7(2):80-5. PubMed ID: 9541091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.